Lundbeck presents new efficacy and safety data analyses for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Lundbeck presents new efficacy and safety data analyses for desmoteplase in patients with acute ischaemic stroke

Valby, Copenhagen, 2014-10-25 11:30 CEST (GLOBE NEWSWIRE) --

  • In the per-protocol population desmoteplase was associated with better functional outcome compared to placebo as assessed by the modified Rankin Scale
  • In additional data analyses it is suggested that magnetic resonance imaging (MRI) is more sensitive than computed tomography (CT) scanning for identifying appropriate patients likely to benefit from desmoteplase
  • In the study the safety profile of desmoteplase was similar to placebo
  • Lundbeck will discuss potential next steps with regulatory authorities
  • Acute ischaemic stroke is a medical emergency and one of the leading causes of death and long-term disability worldwide; no medical treatment is approved in the extended time window of up to 9 hours after onset of symptoms

Valby, Denmark, 25 October 2014 - H. Lundbeck A/S (Lundbeck) today presented additional results from the Desmoteplase in Acute Ischaemic Stroke (DIAS-3) study [i] in patients with acute ischaemic stroke treated in the time window of 3 to 9 hours after onset of symptoms. As communicated on 27 June 2014 there was no significant difference in the primary endpoint, the functional outcome measured by modified Rankin scale (mRS), between patients treated with desmoteplase or placebo at day 90 in the Full Analysis Set (FAS). However, among patients in the per-protocol population treatment with desmoteplase was associated with better functional outcome compared to placebo. The clinical meaning of the observed benefit of desmoteplase is that patients will experience less disability with regard to activities of daily living, even when treated in the extended time-window of up to nine hours.

These findings were presented as a late-breaking session at the 9 th World Stroke Congress (WSC) in Istanbul, Turkey on 25 October 2014.

The assessment of early ischaemic tissue injury and of intracranial cerebral artery obstruction with either computerized tomography (CT) or magnetic resonance imaging (MRI) can be challenging. As a result, several patients were enrolled in the DIAS-3 study who did not meet key imaging inclusion criteria as defined in the study protocol. In the per-protocol population, i.e. among patients who fulfilled pre-specified enrolment criteria, desmoteplase was associated with better functional outcome compared to placebo as measured by mRS at day 90. The scale measures disability or dependence in activities of daily living.

The additional data analyses suggest that MRI is more sensitive than CT for detecting ischaemic injury in patients presenting in the extended time-window. In the pre-specified analysis of patients with <25 ml of early ischaemic injury, treatment with desmoteplase was associated with better functional outcome in those patients who were identified with MRI, however not in those who were selected with CT.  

“ Today most stroke patients are evaluated with a CT scan which can show bleeding in the brain, but may be insufficient for determining the extent of ischaemic injury of the brain tissue ”, said Anders Gersel Pedersen, EVP and head of R&D in Lundbeck. “ Modern MRI technology is a superior method for detecting early ischaemic damage and can help clinicians to determine which patients are likely to benefit from treatment. ”

As previously announced the safety profile of desmoteplase was comparable to that of placebo. The symptomatic intracerebral haemorrhage (sICH) rates in all treated patients were 2.5% (desmoteplase) and 2.1% (placebo) after completion of the study follow-up period to day 90. Further, mortality rates and other safety outcomes were similar in both treatment groups.

Median time from symptom onset to treatment was 7.0 hours.

Considering that no other medication is available for treatment within the nine hour treatment window, the demonstrated effect in the per-protocol population, and the safety and tolerability profile seen in the clinical trials with desmoteplase, further development will be evaluated with advice from key clinical and regulatory experts during the next few months. This evaluation will not be concluded in 2014, but if the outcome is negative a write-down of DKK 330 million will be recognised in the R&D cost line in 2015.

About the DIAS-3 study

DIAS-3 was a multi-centre, randomised, double-blind, placebo-controlled study in 479 patients from 18 countries in Europe and Asia. Patients with symptoms of stroke and a treatable ischaemic stroke pathology (proximal cerebral vessel occlusion/high-grade stenosis without signs of extensive infarction, intracranial haemorrhage or sub-acute infarction), as assessed by magnetic resonance imaging (MRI)  or computerised tomography (CT) scanning were randomised to receive either desmoteplase (90 µg/kg) or placebo within three to nine hours of symptom onset.

About desmoteplase

Desmoteplase, a fibrin-dependent plasminogen activator, is a genetically engineered version of a clot-dissolving protein found in the saliva of the vampire bat Desmodus rotundus. It has received fast-track designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute ischaemic stroke.

About acute ischaemic stroke (AIS)

Stroke is a medical emergency bringing an enormous burden. The annual incidence rate of stroke in the US varies between 150-200 cases per 100,000 people, corresponding to 795,000 cases. For major 5 European countries (France, Germany, Italy, Spain, UK) the incidence rate is estimated at 110-220 cases per 100,000 people a year, resulting in approximately 700,000 cases annually. In Japan, the reported incidence rate is twice as high as that in Europe and the US, i.e. 410 cases per 100,000 people a year, leading to approximately 350,000 cases annually. The overall incidence rate in the less developed countries, traditionally lower than that in the developed countries, has surpassed the latter and is still rising.

S troke is the third leading cause of disability and the second largest cause of mortality globally.

Lundbeck contacts

Investors: Media:
   
Palle Holm Olesen Mads Kronborg
Vice President,  Investor Relations Director, Media Relations
PALO@lundbeck.com MAVK@lundbeck.com
+45 36 43 24 26 +45 36 43 30 00
   
Jens Høyer  
Specialist, Investor Relations  
JSHR@lundbeck.com  
+45 36 43 33 86  
   

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 50 years, we have been at the forefront of research within neuroscience. Our key areas of focus are alcohol dependence, Alzheimer’s disease, bipolar disorder, depression/anxiety, epilepsy, Huntington’s disease, Parkinson’s disease, schizophrenia, stroke and symptomatic neurogenic orthostatic hypotension (NOH).

An estimated 700 million people worldwide are living with brain disease and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain disease – we call this Progress in Mind.

Read more at www.lundbeck.com/global/about-us/progress-in-mind .

Our approximately 6,000 employees in 57 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more 100 countries. We have research centres in China, Denmark and the United States and production facilities in China, Denmark, France and Italy. Lundbeck generated revenue of approximately DKK15.3 billion in 2013 (EUR2.1 billion; USD2.7 billion).

Lundbeck’s shares are listed on the stock exchange in Copenhagen under the symbol ”LUN”. Lundbeck has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol ”HLUYY”. For additional information, we encourage you to visit our corporate site www.lundbeck.com .

Safe Harbor/Forward-Looking Statements

The above information contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance.

Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.

Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Some assumptions, including assumptions relating to sales associated with product that is prescribed for unapproved uses, are made taking into account past performances of other similar drugs for similar disease states or past performance of the same drug in other regions where the product is currently marketed. It is important to note that although physicians may, as part of their freedom to practice medicine in the US, prescribe approved drugs for any use they deem appropriate, including unapproved uses, at Lundbeck, promotion of unapproved uses is strictly prohibited.

[i] ClinicalTrials.gov identifier: NCT00790920

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 157

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading
HashKey and Base Aim to Bridge Asia With Liquidity

Updated Category News Views 79

A blockchain partnership can sound like confetti until the plumbing matters. This one at least points at a real commercial choke point: Asian-originated tokenized assets need deeper pools of global onchain capital, while global networks need credible asset supply and institutional access. HashKey Group's HSK Chain and Coinbase-built Base say they intend to tackle both...

Continue Reading
VisionX AI Bets on Graphs to Track Crypto Crime Nets

Updated Category News Views 91

Money laundering rarely travels in a straight line, and that is precisely the sore spot VisionX AI is trying to jab. The Singapore-based RegTech company has introduced AEGIS, a proprietary Large Graph Model built around financial-crime networks, alongside TraceX, a blockchain investigation platform meant to turn that network view into usable leads. It is a sensible...

Continue Reading
Charter’s $1.5 Billion Tender Tests Debt Discipline

Updated Category News Views 227

Debt cleanup arrives with a hard ceiling Eight far-dated bond issues just got a very specific invitation from Charter Communications: hand them over for cash, but do not expect the company to write a blank check. Charter set final pricing on November 17 for tender offers covering up to $1.5 billion in aggregate consideration, excluding accrued interest and deal expenses....

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 257

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
Azazie Tests Bridal Demand With Two East Coast Pop-Ups

Updated Category News Views 127

Wedding dresses are a miserable product to buy sight unseen, no matter how pretty the product photos look. That basic fact is why Azazie’s two East Coast pop-ups on November 21 and 22 deserve a closer look. This is not some grand retail rollout, and nobody should pretend a pair of short events rewrites the bridal market. But it is a practical test of where a...

Continue Reading
Trinity's Minneapolis Move Signals Freight Momentum

Updated Category News Views 25

A suite change inside downtown Minneapolis is usually wallpaper, but this one carries a little more weight. Trinity Logistics has moved its Minneapolis team from Suite 1850 to Suite 1700 at 100 S. 5th Street, saying the larger space is needed for continued growth and future opportunity. Nobody should confuse an office relocation with a freight-cycle victory lap. Still,...

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 159

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
Markel Elevates War Risk Expertise in London Market

Updated Category News Views 42

A Specialty Desk Gets Its Own Weather Vane War and political violence underwriting is not a corner of insurance where a fancy title change can be shrugged off. The ground shifts under the policyholder, the broker and the carrier without much warning, and a bad call can sit on a book for years. Markel Insurance has named Chloe Gordge Director of War and Political Violence...

Continue Reading
Triple Crossing Tests a Tough Inland Marine Market

Updated Category News Views 182

Inland marine is where tidy insurance appetites go to get bent out of shape. A contractor’s rented machine, cargo moving between points, a half-finished building, or equipment that is neither parked forever nor easy to classify can turn a standard quote into a week of broker phone calls. Triple Crossing Specialty is stepping directly into that mess, launching a new...

Continue Reading

Top 5 Most Recently Viewed Articles

Insights from Key Shareholder Meetings: Tech and Industry Leaders

Updated Category News Views 229

Shareholder Meetings on the Horizon As we move into a new reporting season, the excitement surrounding the upcoming shareholder meetings is palpable. The recent financial results indicate a strong finish to the last quarter, with many companies showcasing impressive growth despite emerging macro challenges. The period after Q4 reporting sees a shift in focus toward the...

Continue Reading
Worldline Welcomes Pierre-Antoine Vacheron as CEO

Updated Category News Views 708

Worldline Welcomes Pierre-Antoine Vacheron as CEO Worldline, a leader in digital payments, has recently announced the appointment of Pierre-Antoine Vacheron as its new Chief Executive Officer. This strategic move, effective from March 1, signals a fresh start for the company as it continues to evolve within the rapidly changing payments industry. A Seasoned Professional...

Continue Reading
Autolus Therapeutics Set to Reveal Q2 2025 Financial Insights

Updated Category News Views 219

Autolus Therapeutics to Release Financial Results Soon Autolus Therapeutics plc (NASDAQ: AUTL), a pioneering biopharmaceutical company, is gearing up to share its financial results for the second quarter of 2025. This announcement is set for shortly before the opening of U.S. markets. As a company focusing on next-generation programmed T cell therapies, the anticipation...

Continue Reading
Brightworks Dentistry Unites Practices Under One Brand

Updated Category News Views 28

New Brand Strategy in Atlanta's Dental Scene In an era where large dental chains seem to gobble up neighborhood practices like some corporate Pac-Man, Dr. Patrice Robbins takes a refreshing turn. Her brainchild, Brightworks Dentistry, is roping in all its Atlanta bases under one banner to keep that local warmth alive. By grouping Dunwoody, Buckhead, and Downtown Atlanta...

Continue Reading
AutoNation's Analyst Coverage Sparks Interest in Key Stocks

Updated Category News Views 48

Recent Insights from Analysts on AutoNation Wall Street analysts have recently published their latest evaluations of several well-known companies, presenting a blend of ratings and insights. In this article, we’ll explore the most recent coverage initiated by leading analysts, focusing specifically on AutoNation, Inc. and other notable companies. Understanding the...

Continue Reading